Castle Biosciences (CSTL) Other Operating Expenses (2019 - 2026)

Castle Biosciences (CSTL) has 8 years of Other Operating Expenses data on file, last reported at $22.8 million in Q1 2026.

• Quarterly Other Operating Expenses fell 49.09% year-over-year to $22.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $83.9 million (down 15.98% YoY) and the FY2025 annual result came in at $105.9 million, up 48.46% from the prior year.
• Other Operating Expenses climbed to $22.8 million in Q1 2026 per CSTL's latest filing, from $20.6 million in the prior quarter.
• The five-year high for Other Operating Expenses was $44.7 million in Q1 2025, with the low at -$10.6 million in Q2 2022.
• Average Other Operating Expenses over 5 years is $16.2 million, with a median of $16.1 million recorded in 2024.
• Year-over-year, Other Operating Expenses sank 368.53% in 2022 and surged 225.35% in 2023.
• Castle Biosciences' Other Operating Expenses stood at $11.4 million in 2022, then climbed by 28.5% to $14.7 million in 2023, then soared by 39.67% to $20.5 million in 2024, then advanced by 0.33% to $20.6 million in 2025, then climbed by 10.53% to $22.8 million in 2026.
• Business Quant data shows CSTL's Other Operating Expenses at $22.8 million in Q1 2026, $20.6 million in Q4 2025, and $21.0 million in Q3 2025.